December 12, 2024

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovators wanted. APPLY NOW!
WE SUPPORT YOUR INNOVATIVE INVENTION!

The work group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnologies in Germany. It annually awards the Innovation Prize of the BioRegions in Germany. This year, the work group again recognizes application-oriented ideas with strong implementation potential and showcases them at the German Biotech Days.

What is awarded?

  • The Innovation Prize honors innovative ideas that are patented or have been submitted for patenting.
  • We seek application-oriented ideas with strong implementation potential and high market opportunities.
  • Our aim is to support outstanding innovations that can significantly contribute to the economy and society.

Who can apply?

  • Scientists from universities and non-university institutions
  • Legal entities under public law, such as universities, universities of applied sciences, or patent exploitation agencies
  • Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What do we offer?

  • Invitation for six finalists to the German Biotech Days on April 9 and 10, 2025, in Heidelberg
  • Presentation to an international audience, financiers, and the trade press
  • Three awards, each worth €2,000
  • An audience award worth €2,000

Apply now!

Application Deadline: February 14, 2025.


Our latest News

discover more
GeneNovate® 2026: Heidelberger Forschende stärken unternehmerisches Denken für die nächste Generation von Gen- und Zelltherapien

GeneNovate® 2026: Heidelberger Forschende stärken unternehmerisches Denken für die nächste Generation von Gen- und Zelltherapien

Heidelberg, Juni 2026 – Mit dem Final Event von GeneNovate® am 25. Juni in der Münchner Residenz endet die dritte Runde des bundesweiten Entrepreneurship-Programms der Nationalen Strategie für gen- und zellbasierte Therapien (Nationale Strategie GCT). Im Rahmen der Abschlussveranstaltung präsentierten Wissenschaftlerinnen und Wissenschaftler aus ganz Deutschland ihre innovativen Geschäftsideen mit Potenzial für zukünftige Gesundheitslösungen und […]

Post-COVID Syndrome: Study Finds Hemodialysis Offers No Benefit to Patients

Post-COVID Syndrome: Study Finds Hemodialysis Offers No Benefit to Patients

A study recently published in *The Lancet Regional Health – Europe* calls into question the benefits of immunoadsorption—a specialized form of blood purification—for post-COVID syndrome. While the autoantibodies, which are thought to be a possible cause of the condition, can be removed from the blood, this does not improve the symptoms of those affected. The […]

Universität Heidelberg: Humboldt Professorship for Leading International Researcher

Universität Heidelberg: Humboldt Professorship for Leading International Researcher

Highly endowed research prize goes to Harvard scientist Mathias Lichterfeld on the proposal of Ruperto Carola In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp